Hemophilia is a bleeding disorder with X-linked inheritance. Current prenatal diagnostic methods for hemophilia are invasive and pose a risk to the fetus. Cell-free fetal DNA analysis in maternal plasma provides a noninvasive mean of assessing fetal sex in such pregnancies. However, the disease status of male fetuses remains unknown if mutation-specific confirmatory analysis is not performed. Here we have developed a noninvasive test to diagnose if the fetus has inherited a causative mutation for hemophilia from its mother. The strategy is based on a relative mutation dosage (RMD) approach which we have previously established for determining the mutational status of fetuses for autosomal disease mutations. In this study, the RMD method is used to deduce if a fetus has inherited a hemophilia mutation on chromosome X by detecting if the concentration of the mutant or wild-type allele is overrepresented in the plasma of heterozygous women carrying male fetuses. We correctly detected fetal genotypes for hemophilia mutations in all of the 12 studied maternal plasma samples obtained from at-risk pregnancies from as early as the 11 th week of gestation. This development would make the decision to undertake prenatal testing less traumatic and safer for at-risk families.
Introduction
Current prenatal diagnostic methods, such as chorionic villus sampling and amniocentesis, are invasive and present an approximately 1% risk of miscarriage. [1] [2] [3] The discovery of cell-free fetal DNA in maternal plasma has offered new opportunities for noninvasive prenatal diagnosis. 4, 5 A number of promising clinical applications have been developed based on the detection of paternally inherited genetic traits in maternal plasma. For example, the noninvasive detection of fetal sex
and RHD status are useful for the clinical management of sex-linked diseases and RhD incompatibility. 6, 7 For monogenic diseases such as achondroplasia and β-thalassemia, the detection of the presence or absence of paternally inherited mutations in maternal plasma would allow one to diagnose autosomal dominant diseases or exclude autosomal recessive diseases of the fetuses, respectively.
8-10
Despite the rapid development of the field, it has remained difficult to detect fetal alleles that are inherited from mothers who are carriers for the mutations. The difficulty is caused by the coexistence of fetal and maternal DNA in maternal plasma, and the maternally inherited fetal allele is indistinguishable from the background maternal DNA. 5 To overcome this problem, we reasoned that the contribution of cellfree fetal DNA to the maternal plasma DNA pool would lead to an increase in total DNA concentration for the allele inherited by the fetus. Hence, the fetal genotype could be deduced by detecting if there is an overrepresentation of the amount of mutant or wild-type allele DNA in maternal plasma. However, the feasibility of this approach is constrained by the low fractional circulating fetal DNA concentration, which typically constitutes only 10% to 20% of total DNA in maternal plasma. 11 As a
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Digital PCR 12 offers a highly sensitive and precise method for quantifying cell-free DNA in maternal plasma. 11 We have developed digital PCR-based methods for measuring allelic imbalance in maternal plasma for the prenatal detection of trisomy 21 and autosomal monogenic diseases. The strategies for analyzing allelic imbalances for the two disease classes are different. For chromosome dosage detection, an overrepresentation of chromosome 21 DNA sequences with reference to unaffected autosomal sequences would indicate a trisomy 21 fetus. 13 For autosomal diseases such as β-thalassemia, we have developed the digital relative mutation dosage (RMD) approach to determine if there is a dosage imbalance between mutant and wild-type alleles in the plasma of heterozygous pregnant women. An allelic balance would be expected for a heterozygous fetus, while an allelic imbalance would be observed for a homozygous fetus. The overrepresented allele would be the one inherited by the fetus.
14 In this study, we further explored the application of the RMD approach in prenatal diagnosis of X-linked disorders, using hemophilia as a disease model. Since female fetuses are affected as carriers, except rare scenarios like skewed Xinactivation, 15 we focused on at-risk women who are carriers for the mutations and are carrying male fetuses. The principal difference between the RMD analyses for autosomal diseases and X-linked diseases is that for the former there are three possible fetal genotypes (i.e. homozygous normal, homozygous mutant, and heterozygous) while for the latter there are only two possible fetal genotypes. In the context of X-linked diseases, a male fetus possesses only one chromosome X and thus 18 Therefore, the development of a noninvasive prenatal diagnostic approach for hemophilia is beneficial to both obstetricians and hemophilia families.
Materials and Methods

Subjects
Seven women who were carriers of hemophilia (three carriers of hemophilia A, four carriers of hemophilia B) and pregnant with male fetuses were recruited from the Royal Free Hospital, London, UK. We also recruited 20 pregnant women (noncarriers of hemophilia) each pregnant with a singleton healthy male fetus. For five of the pregnant hemophilia carriers, peripheral blood samples were taken on two occasions during their pregnancies ( Table 1 ). None of the pregnant hemophilia carriers in this study had invasive prenatal testing. Fetal sex and hemophilia status were confirmed following delivery. For the ten unaffected pregnant women recruited in Hong Kong, placental tissues were also collected following deliveries.
Sample processing
We centrifuged the blood samples at 1600g for 10 min at 4°C. The plasma portion was recentrifuged at 16000g for 10 min at 4°C. Maternal plasma and buffy coat samples were stored at -20°C until further processing. All samples collected in the UK were processed and stored frozen locally and were shipped on dry ice to Hong Kong. We extracted DNA from maternal plasma with the QIAamp DSP DNA Blood Mini Kit (Qiagen) following the manufacturer's instructions. Buffy coat DNA was extracted using the Illustra DNA Extraction Kit (GE Healthcare) following the manufacturer's protocol.
Genotyping of rs6528633 SNP and hemophilia mutations
For the rs6528633 SNP on chromosome X, the fetal and maternal genotypes were determined using DNA obtained from the placental and maternal buffy coat samples, respectively. Genotyping was performed using MassARRAY homogenous 
Digital RMD reactions for maternal plasma analyses
The experimental workflow of digital RMD is illustrated in Figure 1 . We measured the fractional fetal DNA concentrations in the maternal plasma samples using the previously described digital ZFY/X assay, which quantified the homologous ZFY and ZFX gene loci located on chromosomes Y and X, respectively. 11, 14 For the rs6528633 SNP, a real-time PCR assay with two allele-specific TaqMan probes (Applied Biosystems) was designed to distinguish the two SNP alleles. For the mutations of the pregnant cases at risk for hemophilia, a real-time PCR assay for allelic discrimination was designed for each mutation. Each assay contained two allele-specific TaqMan probes for the mutant and the wild-type alleles. The primer and probe sequences are listed in Supplementary Table 1 .
We performed digital PCR analyses on the BioMark System (Fluidigm) using the 12.765 Digital Arrays (Fluidigm). 11 Six of the 12 panels on the Digital Array were used for each DNA sample, which corresponded to 4590 individual PCRs. The reaction for one sample (6 panels) was set up using 2X TaqMan Universal PCR Master Mix (Applied Biosystems) in a reaction volume of 52 μL. The reactions were Array by the NanoFlex IFC Controller (Fluidigm). The reactions were carried out on the BioMark System (Fluidigm). The reactions were initiated at 50°C for 2 minutes, followed by 95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds and assayspecific annealing temperatures (Supplementary Table 1 ) for 1 minute. For a sample that remained unclassified by the RMD with data from one 4590-well digital PCR set, additional 4590-well digital PCR sets were carried out until a genotype call could be made.
Digital PCR data interpretation
We have previously established a strategy for interpreting quantitative data from digital PCR analysis of circulating nucleic acids.
13, 14 For any mutation on chromosome X, there is always an allelic imbalance between the concentrations of the mutant and the wild-type alleles in the plasma of heterozygous women carrying male fetuses. The overrepresented allele is the one inherited by the fetus (Figure 2A ). The calculation of the degree of allelic imbalance is illustrated in Supplementary Table 2 .
We further calculated the ratio of the number of mutant alleles to the total number of mutant and wild-type alleles, denoted by P r , present in the plasma samples. The P r is dependent on the fractional fetal DNA concentration in the samples. The theoretically expected P r for an affected fetus is 1/(2-x), and is (1-x)/(2-x) for a normal fetus, where x is the fractional fetal DNA concentration. We calculated the fractional fetal DNA concentration as previously described. We used the sequential probability ratio test (SPRT) to determine if the dosage imbalance between the mutant and the wild-type alleles in maternal plasma was statistically significant.
13, 14 SPRT simultaneously tested two alternative hypotheses in the case of RMD for chromosome X mutations. The two hypotheses were (i) the mutant allele was over-represented, and (ii) the mutant allele was under-represented.
SPRT was performed by constructing a pair of curves, which defined the probabilistic boundaries for accepting or rejecting the hypotheses ( Figure 2B) . 20, 21 The SPRT curves delineated the required P r (y-axis) for a given total number of positive reactions (x-axis) for classifying a fetal genotype. Hypothesis (i) or (ii) was accepted if the experimental P r fell above the upper boundary or below the lower boundary, respectively. The equations for calculating the SPRT boundaries were adapted from El Karoui et al, 22 with the level of statistical confidence adjusted to a threshold likelihood ratio of 8. 20, 21 The cutoff P r values of the SPRT curves were samplespecific. The cutoff P r values were dependent on the fractional fetal DNA concentration as described above, as well as the average reference template 1 0 concentration per PCR well (m r ). 13, 14 The reference template referred to the allele that showed the lesser positive amplification counts in the sample.
Results
Principle of digital RMD for X-linked polymorphisms
We used digital PCR to measure the concentration difference between the total amount (maternal-plus fetal-derived) of mutant and wild-type alleles in the plasma of heterozygous pregnant women carrying male fetuses. Since a male fetus possesses a single chromosome X, the relative concentration between the wild-type and the mutant allele is always in dosage imbalance (Figure 2A ). An over-or underrepresentation of the mutant allele represents an affected or normal fetus, respectively.
We used SPRT to test for dosage imbalance. A pair of SPRT curves was constructed ( Figure 2B ). Samples with data points above the upper curve or below the lower curve were classified as affected or normal, respectively. Samples with data points in between the two curves were not classified because of insufficient statistical power and additional digital PCRs would be performed.
Noninvasive determination of the fetal genotype for a SNP on chromosome X
We used a SNP, rs6528633 (A/T polymorphism), on chromosome X as a model to assess the practical feasibility of the RMD approach for determining the fetal genotype of a locus on chromosome X. The current RMD analysis is relevant to atrisk pregnant cases, i.e., pregnant women who are heterozygous for mutations on chromosome X and are carrying male fetuses. Hence, we studied the plasma samples from ten pregnant women who were heterozygous for the SNP on chromosome X and 1 1
were carrying male fetuses. We developed an allele-discriminative digital real-time PCR assay to measure the concentrations of the A-and T-allele in each sample. We further measured the fractional fetal DNA concentrations with the ZFY/X assay. The digital RMD result is shown in Table 2 . For all of the cases, the fetal SNP genotypes were concordant with the SPRT classification. The fractional fetal DNA concentrations (fetal % in Table 2 ) ranged from 5% to 24%. The result hence confirmed the feasibility of the digital RMD strategy.
Digital RMD for hemophilia mutation detection in DNA mixtures
We next applied the digital RMD approach for hemophilia mutation detection. We developed seven duplex digital real-time PCR assays to detect three mutations in the F8 gene, four mutations in the F9 gene and their corresponding wild-type counterparts. We evaluated the performance of the digital PCR assays by constructing artificial DNA mixtures that simulated the composition of maternal plasma samples with a minority male fetal DNA component amongst a majority maternal DNA background. We mixed 10% or 20% of placental DNA obtained from an unaffected male fetus with blood cell DNA obtained from women heterozygous for the corresponding mutations. As shown in Table 3 , the genotypes of the placental DNA, which mimicked the fetal DNA in maternal plasma, were correctly detected in all of the DNA mixtures by digital RMD analysis.
Detection of fetal hemophilia mutations in maternal plasma
We tested the digital RMD method for detecting fetal genotypes for the hemophilia mutations through maternal plasma DNA analysis. We carried out digital PCR on 12 plasma samples obtained from seven pregnant women heterozygous for the causative mutations ( Table 1 ). All of the cases involved male fetuses. We also measured the fractional fetal DNA concentrations in the maternal plasma samples by the ZFY/X assay. The digital RMD results are shown in Table 4 . The fetal genotypes were correctly classified in all studied cases by the SPRT algorithm (Supplementary Figure   1 ). For three of the cases (H26a, H25a and H12a), the fetal DNA proportions were less than 10%. Hence, the degree of quantitative difference between the amount of mutant and the wild-type alleles was too small to be classified with data from one 4590-well digital PCR set. Additional 4590-well digital PCR sets were therefore performed until classifications could be made.
As controls, we also studied five maternal plasma samples obtained from normal pregnant women using each of the mutation-specific assays. As shown in Supplementary Table 3 
Discussion
Current prenatal diagnosis for hemophilia largely relies on invasive procedures such as chorionic villus sampling, which pose a finite risk to the fetuses. 1, 2, 23 Consequently, many pregnant women from at-risk families decline invasive testing However, invasive diagnostic testing is still required for half of the pregnant cases involving male fetuses. In this study, we have developed a noninvasive prenatal diagnostic strategy to directly detect causative mutations carried by male fetuses in atrisk pregnancies. By using the digital RMD approach for genetic loci on chromosome X, we have accurately identified the mutant or the wild-type alleles inherited by the male fetuses in all of the 12 studied maternal plasma samples from seven pregnant carriers of hemophilia (Table 4 ). The fetal genotypes could be detected as early as the 11 th week of gestation ( The workflow of noninvasive prenatal hemophilia assessment may be set up as illustrated in Figure 3 . Maternal plasma sample is collected from a pregnant carrier receiving obstetric care. The sex of the fetus is then determined, e.g., by plasma DNA analysis, and no further testing is required for a pregnancy involving a female fetus.
For a pregnancy with a male fetus, digital RMD testing is offered to determine if the fetus has inherited the maternal mutant allele. The digital RMD result could be confirmed, if necessary, by a second maternal plasma sample taken at a later stage of pregnancy when fetal DNA concentrations are higher, 11 allowing for more robust RMD testing. The digital PCRs involved in the current RMD testing were performed on a microfluidics platform. Microfluidics automates the digital reaction setup by channelling nanoliter aliquots of PCR mixture into thousands of amplification chambers. 11 The actual setup of a 4590-well digital PCR set involves only a few manual pipetting steps, and could conveniently be carried out in a routine clinical setting. In addition, the reagents consumed for digital PCRs are relatively inexpensive 1 5
because only a nanoliter-scale of reaction volumes are involved in such reaction chambers. Finally, the system developed in this report can also be applied for the noninvasive prenatal diagnosis of other sex-linked disorders. 33 The reference sequences for hemophilia A and B mutations are F8 mRNA variant 1 (Genbank accession NM_000132.3) and F9 mRNA (NM_000133.3), respectively. Nucleotide position +1 corresponds to the A nucleotide of the ATG translation initiation codon. Amino acid changes deduced from the DNA mutations are shown in the brackets. The reference sequences correspond to coagulation factor VIII isoform a precursor (NP_000123.1) and coagulation factor IX preproprotein (NP_000124.1), respectively. The translation initiator methionine is numbered as position +1. 2 Peripheral blood samples were taken on two occasions from the same women during their pregnancies.
Acknowledgements
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From 
